sb17170
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 17, 2022 (NCT05522868)
Timeline
Indications
Mechanism of action
- High mobility group protein B1INHIBITOR
HMGB1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06846684 | Phase 1 | Mar 27, 2025 | Spark Therapeutics |
| NCT06747923 | Phase 2 | Dec 30, 2024 | Spark Therapeutics |
| NCT05795192 | Phase 1 | May 24, 2023 | Seoul National University, Spark Therapeutics |
| NCT05522868 | Phase 1 | Oct 17, 2022 | Spark Therapeutics |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Spark Therapeutics | For profit | 4 | 4 | 2 | 2022 |
| Seoul National University | Academic/Hospital | 1 | 0 | 1 | 2023 |
2 organizations
Page 1 / 1